Novocure (NVCR) Issues Positive Update on TTFields Study in Certain Glioblastoma Patients

Go back to Novocure (NVCR) Issues Positive Update on TTFields Study in Certain Glioblastoma Patients

Retrospective Analysis Shows Optune Safe in Glioblastoma Patients with Implanted Non-Programmable Shunts

December 3, 2015 4:35 PM EST

Removal of FDA contraindication increases addressable GBM patient population

ST. HELIER, Jersey--(BUSINESS WIRE)-- A retrospective analysis of Novocures (NASDAQ: NVCR) Tumor Treating Fields (TTFields) therapy shows that TTFields therapy is safe in adult glioblastoma patients with implanted non-programmable shunts. The data were presented on Nov. 20 at the 20th Annual Society for Neuro-Oncology Meeting in San Antonio.

The analysis included 1,402 recurrent glioblastoma patients in the U.S. who were treated with TTFields therapy between November 2011 and May 2015. Among those patients, 49 had implanted medical devices: 44 patients had non-programmable shunts,... More